{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:50:13Z","timestamp":1792788613023,"version":"4.5.0"},"reference-count":85,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bradford Hill Clinical Research Center"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Contemporary treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has evolved significantly over the past decade with the introduction of upfront combination therapies (ie, ADT plus androgen receptor pathway inhibitors (ARPIs), with or without docetaxel), previously reserved for more advanced stages of the disease. However, the evidence is still controversial regarding the benefit of triple combinations beyond high volume disease (HVD) compared to double combinations, particularly those consisting of ADT\u2005+\u2005ARPIs. In addition, financial considerations regarding net benefits make these treatment regimens an unfavorable option from a cost-effectiveness standpoint, an element that becomes even more relevant in resource-limited contexts. Considering the lack of head-to-head trials for the direct comparison of triplets vs. ADT\u2005+\u2005ARPIs in different subgroups (as most evidence of specific combination superiority comes from indirect comparison in meta-analyses and the questionable cost-effectiveness profile triplets have shown), we propose that the current role of triplets is reserved for synchronous, HVD mHSPC in a resource-rich setting. Consequently, our work proposes a treatment algorithm that weighs the OS benefit according to the clinical risk of each patient subgroup and the availability of clinical resources. In this current scenario of abundant options, future research will focus on clarifying the selection of the most appropriate treatment for each patient according to their clinical characteristics and re-evaluating the cost-effectiveness of treatments as new drugs and generics emerge.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf095","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T09:28:27Z","timestamp":1748424507000},"source":"Crossref","is-referenced-by-count":12,"title":["Current landscape in first-line treatment of metastatic hormone sensitive prostate cancer: a cost-effectiveness focused review"],"prefix":"10.1093","volume":"30","author":[{"given":"Crist\u00f3bal","family":"\u00c1vila","sequence":"first","affiliation":[{"name":"Urology Department, University of Chile Clinical Hospital. University of Chile , Santiago 8380456 ,\u00a0","place":["Chile"]},{"name":"Basic and Clinical Oncology Department, Faculty of Medicine, University of Chile , Santiago 8380453 ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Gonz\u00e1lez-Montero","sequence":"additional","affiliation":[{"name":"Basic and Clinical Oncology Department, Faculty of Medicine, University of Chile , Santiago 8380453 ,","place":["Chile"]},{"name":"Bradford Hill Clinical Research Center , Santiago 8420000 ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos I","family":"Rojas","sequence":"additional","affiliation":[{"name":"Bradford Hill Clinical Research Center , Santiago 8420000 ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-8636","authenticated-orcid":false,"given":"Ravi A","family":"Madan","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7150-4033","authenticated-orcid":false,"given":"Mauricio","family":"Burotto","sequence":"additional","affiliation":[{"name":"Bradford Hill Clinical Research Center , Santiago 8420000 ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"2025052809282226900_CIT0001","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025052809282226900_CIT0002","volume-title":"Cancer of the Prostate - Cancer Stat Facts"},{"key":"2025052809282226900_CIT0003","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41585-022-00638-6","article-title":"Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future","volume":"19","author":"Van Poppel","year":"2022","journal-title":"Nat Rev Urol"},{"key":"2025052809282226900_CIT0004","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3390\/jpm14070751","article-title":"Understanding the barriers to prostate cancer population-based early detection programs: The PRAISE-U BEST Survey","volume":"14","author":"Beyer","year":"2024","journal-title":"J Pers Med"},{"key":"2025052809282226900_CIT0005","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.eururo.2011.08.026","article-title":"Contemporary role of androgen deprivation therapy for prostate cancer","volume":"61","author":"Pagliarulo","year":"2012","journal-title":"Eur Urol"},{"key":"2025052809282226900_CIT0006","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025052809282226900_CIT0007","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","article-title":"Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review","volume":"10","author":"Hussain","year":"2024","journal-title":"JAMA Oncol"},{"key":"2025052809282226900_CIT0008","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO Guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"key":"2025052809282226900_CIT0009","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"2025052809282226900_CIT0010","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"key":"2025052809282226900_CIT0011","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED Trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2025052809282226900_CIT0012","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"2025052809282226900_CIT0013","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the Randomized Phase 3 GETUG-AFU15 Trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"key":"2025052809282226900_CIT0014","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet (London, England)"},{"key":"2025052809282226900_CIT0015","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"2025052809282226900_CIT0016","doi-asserted-by":"publisher","first-page":"CD012816","DOI":"10.1002\/14651858.CD012816.pub2","article-title":"Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer","volume":"10","author":"Sathianathen","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025052809282226900_CIT0017","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials","volume":"24","author":"Vale","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025052809282226900_CIT0018","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"2025052809282226900_CIT0019","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"2025052809282226900_CIT0020","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"Abiraterone in \u201cHigh-\u201d and \u201cLow-risk\u201d metastatic hormone-sensitive prostate cancer","volume":"76","author":"Hoyle","year":"2019","journal-title":"Eur Urol"},{"key":"2025052809282226900_CIT0021","doi-asserted-by":"publisher","first-page":"CD013245","DOI":"10.1002\/14651858.CD013245.pub2","article-title":"Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer","volume":"12","author":"Sathianathen","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025052809282226900_CIT0022","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2025052809282226900_CIT0023","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2025052809282226900_CIT0024","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"2025052809282226900_CIT0025","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025052809282226900_CIT0026","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"2025052809282226900_CIT0027","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the Randomized, Double-Blind, Phase III TITAN Study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2025052809282226900_CIT0028","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the Phase III ARANOTE Trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025052809282226900_CIT0029","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1200\/jco-24-02314","article-title":"Inferior control arms in prostate cancer trials: The ARANOTE Trial","volume":"43","author":"Mittal","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2025052809282226900_CIT0030","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1200\/jco-24-02742","article-title":"Reply to: inferior control arms in prostate cancer trials: The ARANOTE Trial","volume":"43","author":"Saad","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2025052809282226900_CIT0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2024.11.004","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: an updated network meta-analysis including ARANOTE data","volume":"0","author":"Hoeh","year":"2024","journal-title":"Eur Urol Focus"},{"key":"2025052809282226900_CIT0032","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","article-title":"Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD Trial","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"2025052809282226900_CIT0033","doi-asserted-by":"publisher","first-page":"e1003998","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLoS Med"},{"key":"2025052809282226900_CIT0034","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: A STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"key":"2025052809282226900_CIT0035","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet (London, England)"},{"key":"2025052809282226900_CIT0036","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet (London, England)"},{"key":"2025052809282226900_CIT0037","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"2025052809282226900_CIT0038","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the Phase III ARASENS Trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2025052809282226900_CIT0039","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet (London, England)"},{"key":"2025052809282226900_CIT0040","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11912-024-01509-6","article-title":"Current systemic therapy in men with metastatic castration-sensitive prostate cancer","volume":"26","author":"Grisay","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"2025052809282226900_CIT0041","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.euf.2023.03.024","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer: updated network meta-analysis stratified by disease volume","volume":"9","author":"Hoeh","year":"2023","journal-title":"Eur Urol Focus"},{"key":"2025052809282226900_CIT0042","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.eururo.2022.08.002","article-title":"Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"82","author":"Yanagisawa","year":"2022","journal-title":"Eur Urol"},{"key":"2025052809282226900_CIT0043","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","article-title":"First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"key":"2025052809282226900_CIT0044","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.euo.2022.06.003","article-title":"Addition of docetaxel to androgen receptor axis-targeted therapy and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: a network meta-analysis","volume":"5","author":"Roy","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"2025052809282226900_CIT0045","doi-asserted-by":"publisher","first-page":"E581","DOI":"10.5489\/cuaj.8148","article-title":"UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: metastatic castration-naive and castration-sensitive prostate cancer (Full-text)","volume":"16","author":"So","year":"2022","journal-title":"Can Urol Assoc J"},{"key":"2025052809282226900_CIT0046","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"key":"2025052809282226900_CIT0047","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Comprehensive Cancer Network : JNCCN"},{"key":"2025052809282226900_CIT0048","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1200\/JCO.23.00155","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO Guideline Update","volume":"41","author":"Virgo","year":"2023","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2025052809282226900_CIT0049","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol"},{"key":"2025052809282226900_CIT0050","year":"2019"},{"key":"2025052809282226900_CIT0051","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1097\/JU.0000000000002121","article-title":"Management of patients with metastatic castration-sensitive prostate cancer in the real-world setting in the United States","volume":"206","author":"Ryan","year":"2021","journal-title":"J Urol"},{"key":"2025052809282226900_CIT0052","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2217\/fon-2023-0814","article-title":"Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia","volume":"20","author":"Goebell","year":"2024","journal-title":"Fut Oncol (London, England)"},{"key":"2025052809282226900_CIT0053","doi-asserted-by":"publisher","first-page":"8570","DOI":"10.1002\/cam4.4372","article-title":"Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration","volume":"10","author":"Freedland","year":"2021","journal-title":"Cancer Med"},{"key":"2025052809282226900_CIT0054","doi-asserted-by":"publisher","first-page":"S541","DOI":"10.1016\/j.annonc.2020.08.938","article-title":"679P Treatment patterns of metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study","volume":"31","author":"Tagawa","year":"2020","journal-title":"Ann Oncol"},{"key":"2025052809282226900_CIT0055","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.euo.2023.05.002","article-title":"Does research from clinical trials in metastatic hormone-sensitive prostate cancer treatment translate into access to treatments for patients in the \u201cReal World?\u201d a systematic review","volume":"7","author":"Dodkins","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"2025052809282226900_CIT0056","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/bju.16577","article-title":"Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review","volume":"135","author":"Raval","year":"2025","journal-title":"BJU Int"},{"key":"2025052809282226900_CIT0057","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12894-022-00979-9","article-title":"Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan","volume":"22","author":"Leith","year":"2022","journal-title":"BMC Urol"},{"key":"2025052809282226900_CIT0058","doi-asserted-by":"publisher","first-page":"447.e17","DOI":"10.1016\/j.urolonc.2024.07.002","article-title":"Treatment intensification in metastatic hormone-sensitive prostate cancer: an analysis of real-world practice patterns from the CancerLinQ database","volume":"42","author":"Eule","year":"2024","journal-title":"Urol Oncol"},{"key":"2025052809282226900_CIT0059","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1200\/JOP.091074","article-title":"Impact of the cost of cancer treatment: an internet-based survey","volume":"6","author":"Markman","year":"2010","journal-title":"J Oncol Pract"},{"key":"2025052809282226900_CIT0060","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","article-title":"The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient\u2019s experience","volume":"18","author":"Zafar","year":"2013","journal-title":"Oncologist"},{"key":"2025052809282226900_CIT0061","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jpainsymman.2018.12.003","article-title":"Relationships between financial toxicity and symptom burden in cancer survivors: a systematic review","volume":"57","author":"Chan","year":"2019","journal-title":"J Pain Symptom Manage"},{"key":"2025052809282226900_CIT0062","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","article-title":"Financial insolvency as a risk factor for early mortality among patients with cancer","volume":"34","author":"Ramsey","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025052809282226900_CIT0063","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1001\/jamaoncol.2016.0931","article-title":"An appraisal of clinically meaningful outcomes guidelines for oncology clinical trials","volume":"2","author":"Kumar","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025052809282226900_CIT0064","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"2025052809282226900_CIT0065","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrclinonc.2017.31","article-title":"The high price of anticancer drugs: origins, implications, barriers, solutions","volume":"14","author":"Prasad","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2025052809282226900_CIT0066","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1586\/14737167.8.2.165","article-title":"Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold","volume":"8","author":"Grosse","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2025052809282226900_CIT0067","doi-asserted-by":"publisher","first-page":"1717030","DOI":"10.1080\/20016689.2020.1717030","article-title":"Understanding the global measurement of willingness to pay in health","volume":"8","author":"McDougall","year":"2020","journal-title":"J Mark Access Health Policy"},{"key":"2025052809282226900_CIT0068","doi-asserted-by":"publisher","first-page":"e0297450","DOI":"10.1371\/journal.pone.0297450","article-title":"A systematic review on the direct approach to elicit the demand-side cost-effectiveness threshold: Implications for low- and middle-income countries","volume":"19","author":"Nu","year":"2024","journal-title":"PLoS One"},{"key":"2025052809282226900_CIT0069","doi-asserted-by":"publisher","first-page":"e0266934","DOI":"10.1371\/journal.pone.0266934","article-title":"Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: a systematic review","volume":"17","author":"Iino","year":"2022","journal-title":"PLoS One"},{"key":"2025052809282226900_CIT0070","doi-asserted-by":"publisher","first-page":"e2033787","DOI":"10.1001\/jamanetworkopen.2020.33787","article-title":"Cost-effectiveness of prostate radiation therapy for men with newly diagnosed low-burden metastatic prostate cancer","volume":"4","author":"Lester-Coll","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025052809282226900_CIT0071","doi-asserted-by":"publisher","first-page":"e0277282","DOI":"10.1371\/journal.pone.0277282","article-title":"Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer","volume":"17","author":"Barbier","year":"2022","journal-title":"PLoS One"},{"key":"2025052809282226900_CIT0072","doi-asserted-by":"publisher","first-page":"e12505","DOI":"10.1111\/ecc.12505","article-title":"Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective","volume":"26","author":"Zheng","year":"2017","journal-title":"Eur J Cancer Care (Engl)"},{"key":"2025052809282226900_CIT0073","doi-asserted-by":"publisher","first-page":"380","DOI":"10.5301\/tj.5000583","article-title":"Addition of docetaxel and\/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis","volume":"103","author":"Zhang","year":"2017","journal-title":"Tumori"},{"key":"2025052809282226900_CIT0074","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2217\/cer-2018-0133","article-title":"Comparative clinical effects and cost-effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China","volume":"8","author":"Liu","year":"2019","journal-title":"J Comp Eff Res"},{"key":"2025052809282226900_CIT0075","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41391-019-0161-2","article-title":"Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong\u2019s perspective","volume":"23","author":"Chiang","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2025052809282226900_CIT0076","doi-asserted-by":"publisher","first-page":"e326","DOI":"10.1016\/j.clgc.2021.03.022","article-title":"Cost-effectiveness analysis of innovative therapy for patients with newly diagnosed hormone-sensitive metastatic prostate cancer","volume":"19","author":"Pelloux-Prayer","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"2025052809282226900_CIT0077","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.euo.2018.06.004","article-title":"Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness","volume":"1","author":"Woods","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"2025052809282226900_CIT0078","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.euo.2019.01.004","article-title":"A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer","volume":"2","author":"Sathianathen","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"2025052809282226900_CIT0079","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.urolonc.2019.05.017","article-title":"Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone na\u00efve prostate cancer","volume":"37","author":"Ramamurthy","year":"2019","journal-title":"Urol Oncol"},{"key":"2025052809282226900_CIT0080","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.clgc.2022.04.014","article-title":"Treatment of patients with metastatic hormone-sensitive prostate cancer: a systematic review of economic evaluations","volume":"20","author":"Pelloux-Prayer","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"2025052809282226900_CIT0081","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2021.10.016","article-title":"Cost-effectiveness of systemic treatments for metastatic castration-sensitive prostate cancer: an economic evaluation based on network meta-analysis","volume":"25","author":"Wang","year":"2022","journal-title":"Value Health : J Int Soc Pharmacoecon Outc Res"},{"key":"2025052809282226900_CIT0082","doi-asserted-by":"publisher","first-page":"627083","DOI":"10.3389\/fonc.2021.627083","article-title":"A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer","volume":"11","author":"Sung","year":"2021","journal-title":"Front Oncol"},{"key":"2025052809282226900_CIT0083","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1093\/jnci\/djad135","article-title":"Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective","volume":"115","author":"Yoo","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"2025052809282226900_CIT0084","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.euo.2023.11.013","article-title":"Cost effectiveness of systemic treatment intensification for metastatic hormone-sensitive prostate cancer: is triplet therapy cost effective","volume":"7","author":"Sathianathen","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"2025052809282226900_CIT0085","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/GO.20.00505","article-title":"Consensus for treatment of metastatic castration-sensitive prostate cancer: report from the first global prostate cancer consensus conference for developing countries (PCCCDC)","volume":"7","author":"Maluf","year":"2021","journal-title":"JCO Glob Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf095\/63391617\/oyaf095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf095\/63391617\/oyaf095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T09:28:28Z","timestamp":1748424508000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf095\/8152114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":85,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf095","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5]]},"article-number":"oyaf095"}}